Mutation in genes that activate multiple signaling pathways for e.g., mTOR and its inhibition by everolimus is a pharmacologic approach to target mutant TP53 reported to be activated in breast and pancreatic cancer cell lines. The gene discussed is TP53; the disease is pancreatic neoplasm.